Krystal Biotech, INC Form 4 insider transactions

Dino A Rossi, a Director of Krystal Biotech, Inc., sold 25,000 shares of common stock on August 14, 2026.

Krystal Biotech's EVP, General Counsel, Thomas John Charles, executed a Rule 10b5-1 trading plan, selling 1,000 shares of common stock.

Suma Krishnan, President of R&D at Krystal Biotech, sold 25,178 shares of common stock on June 4, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Krystal Biotech CEO Krish S. Krishnan sold 25,000 shares of common stock on June 4, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

John C. Thomas, EVP and General Counsel of Krystal Biotech, sold 642 shares of common stock under a pre-established Rule 10b5-1 trading plan.

Krystal Biotech's President of R&D, Suma Krishnan, sold 25,000 shares of common stock for over $6.5 million under a pre-arranged 10b5-1 trading plan.

Krystal Biotech's President and CEO, Krish S. Krishnan, sold 25,928 shares of common stock on March 4, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech's Chief Accounting Officer, Kathryn Romano, reported a series of equity transactions including vesting of performance and restricted stock units, tax-related dispositions, a planned stock sale, and new equity grants.

Suma Krishnan, President of R&D at Krystal Biotech, reported significant vesting of equity awards and new grants, alongside tax-related share dispositions.

Krystal Biotech's President and CEO, Krish S. Krishnan, reported multiple equity transactions including RSU and PSU vestings, tax withholdings, and new stock option and RSU grants.

Krystal Biotech Director Daniel Janney sold 11,803 shares of common stock for approximately $3.25 million under a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech Director Daniel Janney exercised options and sold common stock, both directly and indirectly through Alta Bioequities, L.P., under a pre-arranged 10b5-1 trading plan.

Krystal Biotech Director Dino A. Rossi exercised stock options and subsequently sold an equal number of common shares under a Rule 10b5-1 plan.

Krystal Biotech's Chief Accounting Officer, Kathryn Romano, exercised stock options and subsequently sold a significant portion of the acquired shares, alongside a charitable gift, under a pre-arranged 10b5-1 trading plan.

Krystal Biotech's President of R&D, Suma Krishnan, and her spouse sold a combined 49,800 shares and gifted 5,000 shares of common stock.

Krystal Biotech's President and CEO, Krish S. Krishnan, and his spouse reported sales and a gift of company common stock totaling 55,000 shares.

Krystal Biotech's President of R&D, Suma Krishnan, and her spouse have completed sales of company common stock totaling over $5.3 million through pre-arranged Rule 10b5-1 trading plans, which have now terminated.

Krystal Biotech's President and CEO, Krish S. Krishnan, and his spouse have completed sales of Krystal Biotech common stock totaling 35,773 shares through pre-arranged Rule 10b5-1 trading plans.

Suma Krishnan, President of R&D and a 10% owner of Krystal Biotech, along with her spouse, sold a combined total of 14,127 shares of common stock in early July 2025, pursuant to pre-arranged Rule 10b5-1 trading plans.

Krystal Biotech's President and CEO, Krish S. Krishnan, and his spouse, Suma M. Krishnan, reported the sale of 14,127 shares of common stock totaling approximately $2.12 million through pre-arranged Rule 10b5-1 trading plans on July 9 and 10, 2025.

Krystal Biotech, Inc. Director Julian S. Gangolli was granted 5,000 stock options with an exercise price of $137.46, vesting monthly over one year, effective June 30, 2025.

Krystal Biotech, Inc. Director Everett Rand Sutherland was granted 5,000 stock options with an exercise price of $137.46, vesting monthly over one year.

Krystal Biotech, Inc. Director Daniel Janney was granted 5,000 stock options with an exercise price of $137.46, effective June 30, 2025, as part of his compensation.

Krystal Biotech, Inc. Director Christopher Mason was granted 5,000 stock options with an exercise price of $137.46, vesting monthly over one year.

Krystal Biotech, Inc. Director Dino A. Rossi was granted 5,000 stock options with an exercise price of $137.46, vesting over one year, effective June 30, 2025.

Krystal Biotech, Inc. Director Catherine Mazzacco was granted 5,000 stock options with an exercise price of $137.46, vesting monthly over one year.

Suma Krishnan, a Director and Officer at Krystal Biotech, sold shares of common stock on March 13, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech's CEO, Krish Krishnan, and his spouse executed multiple sales of common stock on March 13, 2025, under pre-arranged 10b5-1 trading plans.

Kathryn Romano, Chief Accounting Officer of Krystal Biotech, reports multiple transactions involving common stock, including acquisitions, disposals, and vesting of performance stock units and restricted stock units.

Suma Krishnan, President of R&D at Krystal Biotech, reports multiple transactions involving common stock and derivative securities, including acquisitions, disposals, and vesting of performance stock units and restricted stock units.